These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 27860138)

  • 1. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S; Chu C; Rong A
    Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
    Wu J
    J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculation for the proportional hazards cure model.
    Wang S; Zhang J; Lu W
    Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
    Wei J; Wu J
    Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy trial design with long-term survivors.
    Ding X; Wu J
    Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C; Liu S; Rong A
    Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint.
    Li Z; Geng X; Hou Y; Chen Z
    Stat Methods Med Res; 2024 Sep; 33(9):1546-1558. PubMed ID: 39106345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy trial design with delayed treatment effect.
    Wu J; Wei J
    Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On sample size calculation for comparing survival curves under general hypothesis testing.
    Jung SH; Chow SC
    J Biopharm Stat; 2012; 22(3):485-95. PubMed ID: 22416836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z; Zhang Q; Xue A; Whitmore J
    Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J; Wei J
    Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design considerations in clinical trials with cure rate survival data: A case study in oncology.
    Sun S; Liu G; Lyu T; Xue F; Yeh TM; Rao S
    Pharm Stat; 2018 Mar; 17(2):94-104. PubMed ID: 29159922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.
    Wu J
    Stat Biopharm Res; 2017; 9(1):25-34. PubMed ID: 28966721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.